The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemically pure form; 2) assessment of the biological activity of each stereo chemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs. 

Nonprofit

• Other Native American tribal organizations
• Nonprofits non-higher education without 501(c)(3)
• Nonprofits non-higher education with 501(c)(3)

Education

• Public and state institutions of higher education
• Private institutions of higher education
• Independent school districts

Business

• For-profit organizations other than small businesses
• Small businesses

Government

• Federally recognized Native American tribal governments
• State governments
• Special district governments
• County governments
• City or township governments
• Public and Indian housing authorities

Miscellaneous

• Unrestricted
• Other